![Jesse Cotari](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Jesse Cotari is associated with ImmuneBridge, Inc. as the Chief Scientific Officer since 2018.
Dr. Cotari is the founder of ImmuneBridge, Inc. which was founded in 2018.
Posizioni attive di Jesse Cotari
Società | Posizione | Inizio |
---|---|---|
ImmuneBridge, Inc.
![]() ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Fondatore | 01/01/2018 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
ImmuneBridge, Inc.
![]() ImmuneBridge, Inc. BiotechnologyHealth Technology ImmuneBridge, Inc. is a biotech company that is developing the next generation of allogeneic cellular medicines to make curative cancer therapies accessible to everyone. The company is based in San Francisco, CA and was founded in 2018 by Jesse Cotari and Peretz Partensky. The company is starting with NK cell-based immunotherapies. The company's proprietary expansion technology amplifies cord blood-derived immune stem cells while maintaining full immune multipotency to create a consistent and abundant cellular source for immunotherapies. ImmuneBridge's scientific approach harnesses this expansion technology along with the unique benefits of umbilical cord blood to enable robust screening and selection for the most potent cancer-fighting cells. Peretz Partensky has been the CEO since 2018. | Health Technology |
- Borsa valori
- Insiders
- Jesse Cotari